Canadian Vaping Association’s response to Canada Gazette, Part 1
Canadian Vaping Association’s response to Canada Gazette, Part 1
Beamsville, ON, Dec. 18, 2020 With today’s release of the Canada Gazette, Part 1, the Canadian Vaping Association (CVA) has learned of the federal government’s intention to restrict nicotine concentrations to 20mg/mL. The CVA believes that this decision is not without merit; however, restricting high nicotine content to age-restricted specialty vape shops would better balance youth protection with adult harm reduction.
As research has concluded that youth vape for nicotine, it is reasonable for the federal government to restrict it. Yet, the government can not allow adult smokers who require high nicotine concentrations to remain smoke-free to be left behind. The survey “Smokefree GB”, conducted by Action on Health and Smoking found that despite nicotine in Great Britain being limited to 20mg/mL, 2% of vapers reported using a strength grea
LEADING ROSEN LAW FIRM Continues its Investigation of Securities Claims Against Qiwi plc – QIWI
LEADING ROSEN LAW FIRM Continues its Investigation of Securities Claims Against Qiwi plc – QIWI
NEW YORK, Dec. 11, 2020 Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiwi plc (NASDAQ: QIWI) resulting from allegations that Qiwi may have issued materially misleading business information to the investing public.
On December 9, 2020, Qiwi issued a press release entitled “QIWI (QIWI) Fined by Bank of Russia, Restricts Operations.” The press release stated, in relevant part, that “[f]rom July to December 2020, the Central Bank of Russia (‘CBR’), acting in its supervisory capacity, performed a routine scheduled audit of Qiwi Bank JSC (‘Qiwi Bank’) for the period of July 2018 to September 2020 and, in the course of this audit, has identified certain violations and deficiencies relating pr
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
AUSTIN, Texas, Dec. 18, 2020 Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.
H.C. Wainwright BioConnect 2021 Conference
A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Monday, January 11, 2021, through the H.C. Wainwright conference portal and on Lumos Pharma’s website under “
Events & Presentations” in the Investors & Media section. The webcast will be available on Lumos Pharma’s website for 30 days.
Independence Gold Grants Incentive Stock Options
VANCOUVER, British Columbia, Dec. 18, 2020
Independence Gold Corp. (TSX.V: IGO) (the “Company”) wishes to announce the granting of incentive stock options to certain consultants and employees to purchase up to 550,000 common shares under the Company’s Incentive Stock Option Plan. The options will be granted for a period of five (5) years, commencing on December 18, 2020, exercisable at a price of $0.18 per share.
ON BEHALF OF THE BOARD of Independence Gold Corp.
“Randy Turner”
Randy Turner, President and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SUSS MicroTec Opens New Production Facility in Taiwan
SUSS MicroTec Opens New Production Facility in Taiwan SUSS MicroTec, a leading provider of systems and process solutions for the semiconductor industry and related markets, is opening the doors of its new production facility in HsinChu, Taiwan. The company is responding to increased industry demand due to booming applications and megatrends such as 5G, IoT, AI and mobility. With the new production site, the company will achieve even greater flexibility to be able to specifically meet the wishes of customers, such as accelerated lead, delivery and response times. The Asian customer base in particular will benefit from this added flexibility. In addition, even closer collaboration on current and future product generations can result from the proximity of application support and production to strategic key customers.